Elypta’s urine test shows game-changing potential in kidney cancer follow-up
Elypta announced that findings from the international AURORAX-0087A (AUR87A) study were presented in a Plenary Game Changer Session at the 2025 European Association of Urology Congress.
The AUR87A study, conducted across 29 hospitals in the UK, EU, USA, and Canada, evaluates the use of glycosaminoglycans (GAGomes) as urine-derived metabolic biomarkers to monitor kidney cancer recurrence in patients following surgery.
The intermediary results show that the test correctly identified 90% of patients with recurrent cancer. Notably, a negative score corresponded to a 97% probability of being recurrence-free.
This high negative predictive value supports Elypta’s belief that post-treatment monitoring of cancer patients needs to be transformed. Instead of undergoing repeated radiological exams – a process that can both expose the patient to radiation and constitute a significant burden – patients could submit a simple urine sample.
